# Silo Pharma, Inc.: overview SILO · Nasdaq · CIK 1514183 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/silo.md) · [Financials](/companies/silo/financials.md) · [Filings](/companies/silo/filings.md) · [Insiders](/companies/silo/insiders.md) Latest reported revenue: [$0](/filings/0001213900-26-089085.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001213900-26-089085). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [18.0](/filings/0001213900-25-110006.md) | [18.0 d](/filings/0001213900-26-035576.md) | [18.0](/filings/0001213900-26-056079.md) | [18.0](/filings/0001213900-26-089085.md) | [18.0](/filings/0001213900-25-110006.md) | [18.0 d](/filings/0001213900-26-035576.md) | [18.0](/filings/0001213900-26-056079.md) | [0.0 d](/filings/0001213900-26-089085.md) | | Gross margin | % | [91.9%](/filings/0001213900-25-110006.md) | [91.9% d](/filings/0001213900-26-035576.md) | [91.9%](/filings/0001213900-26-056079.md) | [91.9%](/filings/0001213900-26-089085.md) | [(14.8%)](/filings/0001213900-25-110006.md) | [(14.8%) d](/filings/0001213900-26-035576.md) | [(14.8%)](/filings/0001213900-26-056079.md) | not reported | | Operating margin | % | [(5603.6%)](/filings/0001213900-25-110006.md) | [(10059.6%) d](/filings/0001213900-26-035576.md) | [(6069.7%)](/filings/0001213900-26-056079.md) | [(6926.8%)](/filings/0001213900-26-089085.md) | [(6388.2%)](/filings/0001213900-25-110006.md) | [(4363.3%) d](/filings/0001213900-26-035576.md) | [(8846.4%)](/filings/0001213900-26-056079.md) | not reported | | Net margin | % | [(5152.9%)](/filings/0001213900-25-110006.md) | [(9600.7%) d](/filings/0001213900-26-035576.md) | [(5721.9%)](/filings/0001213900-26-089085.md) | [(6681.2%)](/filings/0001213900-26-089085.md) | [(6160.5%)](/filings/0001213900-25-110006.md) | [(4890.3%) d](/filings/0001213900-26-035576.md) | [(9137.5%)](/filings/0001213900-26-089085.md) | not reported | | Diluted EPS | $ per share | [(0.22)](/filings/0001213900-25-110006.md) | not reported | [(0.23)](/filings/0001213900-26-056079.md) | [(2.88)](/filings/0001213900-26-089085.md) | [(0.12)](/filings/0001213900-25-110006.md) | not reported | [(0.12)](/filings/0001213900-26-056079.md) | [(0.76)](/filings/0001213900-26-089085.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | [72.1](/filings/0001213900-24-025615.md) | [72.1](/filings/0001013762-25-004139.md) | [72.1](/filings/0001213900-26-035576.md) | [72.1](/filings/0001213900-26-035576.md) | | Gross margin | % | not reported | [91.9%](/filings/0001213900-24-025615.md) | [91.9%](/filings/0001013762-25-004139.md) | [91.9%](/filings/0001213900-26-035576.md) | [38.6%](/filings/0001213900-26-035576.md) | | Operating margin | % | not reported | [(5031.3%)](/filings/0001213900-24-025615.md) | [(5347.4%)](/filings/0001013762-25-004139.md) | [(6526.4%)](/filings/0001213900-26-035576.md) | [(5937.0%)](/filings/0001213900-26-035576.md) | | Net margin | % | not reported | [(5420.9%)](/filings/0001213900-24-025615.md) | [(5132.6%)](/filings/0001013762-25-004139.md) | [(6092.6%)](/filings/0001213900-26-035576.md) | [(5863.5%)](/filings/0001213900-26-035576.md) | | Diluted EPS | $ per share | [0.04](/filings/0001213900-22-015521.md) | not reported | [(1.20)](/filings/0001013762-25-004139.md) | [(1.19)](/filings/0001213900-26-035576.md) | [(0.50)](/filings/0001213900-26-035576.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/silo/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $469.4k | 75,582 | | New +75,582 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $104.3k | 16,800 | | New +16,800 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $74.2k | 11,956 | | New +11,956 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $5.4k | 874 | | New +874 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $1.1k | 181 | | New +181 | | [FNY Investment Advisers, LLC](/funds/1742998.md) | 2026-06-30 | $232 | 37,507 | | New +37,507 | | [HARBOUR INVESTMENTS, INC.](/funds/810121.md) | 2026-06-30 | $87 | 14 | | New +14 | | [CITIGROUP INC](/funds/831001.md) | 2026-06-30 | $6 | 1 | | New +1 | ## Recent filings [All 378 filings](/companies/silo/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-14 | 20:30 ET | [8-K](/filings/0001213900-26-109457.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-109457 | | 2026-10-02 | 20:37 ET | [8-K](/filings/0001213900-26-106435.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-106435 | | 2026-08-19 | 21:17 ET | [8-K](/filings/0001213900-26-091783.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-091783 | | 2026-08-17 | 20:05 ET | [8-K](/filings/0001213900-26-090748.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001213900-26-090748 | | 2026-08-13 | 20:06 ET | [10-Q](/filings/0001213900-26-089085.md) | Quarterly report, period 2026-06-30 | 0001213900-26-089085 | | 2026-07-13 | 22:29 ET | [8-K](/filings/0001213900-26-077296.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-077296 | | 2026-06-30 | 11:06 ET | [DEF 14A](/filings/0001213900-26-073367.md) | Proxy statement, period 2026-08-14 | 0001213900-26-073367 | | 2026-06-18 | 21:15 ET | [8-K](/filings/0001213900-26-070212.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-070212 | | 2026-06-03 | 21:00 ET | [8-K](/filings/0001213900-26-064804.md) | 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-064804 | | 2026-06-01 | 13:02 ET | [8-K](/filings/0001213900-26-063185.md) | 8.01 Other events | 0001213900-26-063185 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-035576.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c92068c4-7c75-4eed-82e3-3997be455243) ## About the filer - CIK: 1514183 - Tickers: SILO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.